Login to Your Account



BMS Stumble in HCV Trial Could Prove Gilead's Gain

By Mari Serebrov
Washington Editor

Friday, August 3, 2012
In the heat of the race for an interferon-free treatment for hepatitis C virus (HCV), Bristol-Myers Squibb Co. (BMS) stumbled over a serious safety issue in a Phase IIb trial of BMS-986094.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription